Sterling Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.27M | Buy |
66,500
+13,470
| +25% | +$1.89M | 0.18% | 110 |
|
|
2025
Q4 | $6.51M | Buy |
53,030
+2,999
| +6% | +$364K | 0.11% | 160 |
|
|
2025
Q3 | $5.55M | Sell |
50,031
-3,705
| -7% | -$421K | 0.08% | 162 |
|
|
2025
Q2 | $5.96M | Buy |
53,736
+16,018
| +42% | +$1.7M | 0.08% | 159 |
|
|
2025
Q1 | $4.23M | Sell |
37,718
-9,946
| -21% | -$1.03M | 0.07% | 200 |
|
|
2024
Q4 | $4.4M | Buy |
47,664
+42,040
| +748% | +$3.79M | 0.06% | 243 |
|
|
2024
Q3 | $472K | Buy |
+5,624
| New | +$429K | 0.01% | 894 |
|
|
2019
Q3 | $72.2M | Buy |
1,138,834
+77,360
| +7% | +$5.06M | 0.68% | 45 |
|
|
2019
Q2 | $71.7M | Buy |
1,061,474
+625
| +0.1% | +$41.1K | 0.69% | 53 |
|
|
2019
Q1 | $69M | Buy |
1,060,849
+36,675
| +4% | +$2.44M | 0.68% | 48 |
|
|
2018
Q4 | $64.1M | Sell |
1,024,174
-63,719
| -6% | -$4.45M | 0.7% | 49 |
|
|
2018
Q3 | $84M | Sell |
1,087,893
-17,085
| -2% | -$1.29M | 0.76% | 42 |
|
|
2018
Q2 | $78.3M | Sell |
1,104,978
-110,035
| -9% | -$7.77M | 0.73% | 49 |
|
|
2018
Q1 | $91.6M | Buy |
1,215,013
+17,233
| +1% | +$1.37M | 0.86% | 28 |
|
|
2017
Q4 | $85.8M | Sell |
1,197,780
-21,991
| -2% | -$1.67M | 0.78% | 40 |
|
|
2017
Q3 | $98.8M | Buy |
1,219,771
+56,020
| +5% | +$4.28M | 0.93% | 25 |
|
|
2017
Q2 | $82.4M | Buy |
1,163,751
+15,144
| +1% | +$1.01M | 0.79% | 39 |
|
|
2017
Q1 | $78M | Buy |
1,148,607
+85,179
| +8% | +$5.99M | 0.73% | 40 |
|
|
2016
Q4 | $76.2M | Sell |
1,063,428
-42,978
| -4% | -$3.19M | 0.69% | 50 |
|
|
2016
Q3 | $87.5M | Buy |
1,106,406
+155,955
| +16% | +$12.7M | 0.81% | 44 |
|
|
2016
Q2 | $79.3M | Buy |
950,451
+426,623
| +81% | +$37.9M | 0.72% | 48 |
|
|
2016
Q1 | $48.1M | Buy |
523,828
+439,723
| +523% | +$39.7M | 0.44% | 83 |
|
|
2015
Q4 | $8.51M | Buy |
84,105
+3,914
| +5% | +$407K | 0.08% | 185 |
|
|
2015
Q3 | $7.87M | Buy |
80,191
+11,991
| +18% | +$1.33M | 0.07% | 187 |
|
|
2015
Q2 | $7.99M | Sell |
68,200
-1,962
| -3% | -$214K | 0.07% | 137 |
|
|
2015
Q1 | $6.88M | Buy |
70,162
+8,140
| +13% | +$827K | 0.06% | 156 |
|
|
2014
Q4 | $5.85M | Buy |
62,022
+1,794
| +3% | +$186K | 0.05% | 170 |
|
|
2014
Q3 | $6.41M | Sell |
60,228
-9,115
| -13% | -$893K | 0.08% | 147 |
|
|
2014
Q2 | $5.75M | Buy |
69,343
+56,909
| +458% | +$4.43M | 0.05% | 158 |
|
|
2014
Q1 | $881K | Buy |
12,434
+2,181
| +21% | +$171K | 0.01% | 633 |
|
|
2013
Q4 | $770K | Buy |
10,253
+2,512
| +32% | +$175K | 0.01% | 434 |
|
|
2013
Q3 | $487K | Sell |
7,741
-78,385
| -91% | -$4.68M | 0.01% | 404 |
|
|
2013
Q2 | $4.42M | Buy |
+86,126
| New | +$4.49M | 0.05% | 160 |
|
Other funds holding GILD
VCM
VPM
Sterling Capital Management's GILD Position: Q1 2026 in Review
Sterling Capital Management increased its Gilead Sciences (GILD) stake by 25% in Q1 2026, buying an estimated $1.89M and bringing the position to 66,500 shares worth $9.27M. The position accounts for 0.18% of the portfolio, ranked #110.
Sterling Capital Management first reported a position in GILD in Q2 2013 and has held it in 33 quarters since. The position peaked at $98.8M in Q3 2017. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Sterling Capital Management held 66,500 shares of Gilead Sciences worth $9.27M as of Q1 2026.
- Sterling Capital Management bought 13,470 Gilead Sciences shares in Q1 2026, an estimated $1.89M.
- Gilead Sciences made up 0.18% of Sterling Capital Management's portfolio in Q1 2026, its #110 holding.
- Sterling Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 33 quarters since.
- Sterling Capital Management's Gilead Sciences position peaked at $98.8M in Q3 2017.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.